Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Rhythm Pharmaceuticals Inc (RYTM)

Rhythm Pharmaceuticals Inc (RYTM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Melanocortin Receptor R&D to Target Increasing Prevalence of Obesity-Related Disorders FinancialNewsMedia - Thu Oct 19, 2023

EQNX::TICKER_START (NYSE:PTN),(NASDAQ:RYTM),(NASDAQ:VKTX),(NASDAQ:GPCR),(NYSE:NVO) EQNX::TICKER_END

PTN : 1.8400 (-2.13%)
RYTM : 41.57 (-1.82%)
VKTX : 50.25 (-2.50%)
GPCR : 37.98 (-1.94%)
NVO : 137.42 (-3.89%)
Melanocortin Receptor R&D to Target Increasing Prevalence of Obesity-Related Disorders PR Newswire - Thu Oct 19, 2023

/PRNewswire/ -- The Melanocortin Receptor 4 (MC4R) is a protein-coupled receptor primarily expressed in the central nervous system, playing a pivotal role in...

PTN : 1.8400 (-2.13%)
RYTM : 41.57 (-1.82%)
VKTX : 50.25 (-2.50%)
GPCR : 37.98 (-1.94%)
NVO : 137.42 (-3.89%)
What Will Amgen Buy Next? Motley Fool - Thu Jun 29, 2023

The biotech could pursue these two budget-friendly targets.

REGN : 1,016.91 (-2.66%)
AMGN : 307.80 (-0.96%)
HZNP : 116.30 (+0.04%)
NTLA : 22.78 (+2.84%)
RYTM : 41.57 (-1.82%)
3 Breakout Growth Stocks to Buy for the Long Haul Motley Fool - Mon Jan 9, 2023

These three have had big-time share gains backed up by breakthrough science.

BLTE : 45.70 (+0.44%)
TMDX : 150.36 (+0.93%)
RYTM : 41.57 (-1.82%)
Wall Street - Wall Street Sign NYSE
Stocks Mixed As Fed Rate Hike Looms Barchart - Thu Sep 15, 2022

September S&P 500 futures (ESU22) are moderately up +0.03% this morning after three major US benchmark indices bounced back during the regular session as an on-target inflation report mainly stopped the...

ESU22 : 3,871.24s (-0.79%)
APA : 29.48 (+0.41%)
RYTM : 41.57 (-1.82%)
IRNT : 0.0002 (unch)
AKRO : 21.79 (-2.64%)
RIVN : 14.64 (-1.68%)
NEE : 71.81 (+1.90%)
FSR : 0.0897 (-28.13%)
PANW : 341.80 (+0.40%)
ERIC : 6.20 (+0.08%)
3 Healthcare Stocks That Are Beating the Market Motley Fool - Sun Aug 28, 2022

Here's why our roundtable is bullish on Shockwave Medical, Axsome Therapeutics, and Rhythm Pharmaceuticals.

SWAV : 334.75 (-0.02%)
AXSM : 79.87 (+1.19%)
RYTM : 41.57 (-1.82%)
What Bear Market? These 3 Stocks Have Been Rocketing Higher in 2022 Motley Fool - Thu Aug 25, 2022

These three healthcare stocks have defied the 2022 bear market.

COMP : 3.54 (+0.28%)
RYTM : 41.57 (-1.82%)
SIGA : 7.79 (-0.13%)
VERU : 0.9088 (-4.70%)
Rhythm Pharmaceuticals to Present at Canaccord Genuity 42nd Annual Growth Conference Globe Newswire - Wed Aug 3, 2022

BOSTON, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on...

RYTM : 41.57 (-1.82%)
Why Rhythm Pharmaceuticals Stock Is Rocketing Higher Today Motley Fool - Tue Aug 2, 2022

The biotech's second-quarter earnings report is a big hit with shareholders.

RYTM : 41.57 (-1.82%)
Rhythm Pharmaceuticals Reports Second Quarter 2022 Financial Results and Business Update Globe Newswire - Tue Aug 2, 2022

-- Received FDA approval for IMCIVREE® (setmelanotide) as the first-ever therapy for patients with Bardet-Biedl syndrome -- -- U.S. launch off to a...

RYTM : 41.57 (-1.82%)

Barchart Exclusives

This 'Boring' Copper Miner Is Outfoxing Its Competitors Barchart - 28 minutes ago
Investors underestimating the rate at which Rio Tinto is evolving. Its $15 billion investment into the giant Oyu Tolgoi copper mine in Mongolia gives Rio the potential to catch up to BHP in terms of production – it could produce close to 900,000 tons by the end of the decade, a 50% increase from 2023. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot